Dr Terry Hart moves to Peakdale
Peakdale Molecular has appointed Dr Terry Hart to the its Board of Directors as medicinal chemistry services director 'in order to drive further medicinal chemistry capabilities' and enhance its range of services.
Peakdale Molecular has appointed Dr Terry Hart to the its Board of Directors as medicinal chemistry services director 'in order to drive further medicinal chemistry capabilities' and enhance its range of services.
Hart has over 20 years of pharmaceutical experience, and his new role has been created to add further value to customers' drug discovery activities. He will be responsible for applying the latest medicinal chemistry knowledge and his extensive drug discovery experience to further support pharmaceutical and biotech customers' drive for new drugs.
He joins Peakdale from the Novartis Institute for Biomedical Research where he was unit head of discovery chemistry for seven years. While there he co-invented several compounds that are currently in clinical trials for pain, anxiety and depression. He has also been a director of medicinal chemistry within the Biotech industry; invented RAPiD (Rational Approach to Protease Inhibitor Design), a patented, combinatorial mapping and protease inhibitor design technology; and spent 17 years at Rhone-Poulenc Rorer where he designed and synthesised several clinical candidates and was leader of the Taxotere programme.